461 related articles for article (PubMed ID: 7564784)
1. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.
Nishiguchi S; Kuroki T; Nakatani S; Morimoto H; Takeda T; Nakajima S; Shiomi S; Seki S; Kobayashi K; Otani S
Lancet; 1995 Oct; 346(8982):1051-5. PubMed ID: 7564784
[TBL] [Abstract][Full Text] [Related]
2. Effects of interferon alpha 2a on incidence of hepatocellular carcinoma in chronic active hepatitis without cirrhosis. Hepatitis Treatment Study Group.
Sata M; Ide T; Akiyoshi F; Fukuizumi K; Noguchi S; Shirachi M; Sasaki M; Uchimura Y; Suzuki H; Tanikawa K
Kurume Med J; 1997; 44(3):171-7. PubMed ID: 9339647
[TBL] [Abstract][Full Text] [Related]
3. Long-term evaluation of interferon therapy in hepatitis C virus-associated cirrhosis: does IFN prevent development of hepatocellular carcinoma?
Tanaka K; Sata M; Uchimura Y; Suzuki H; Tanikawa K
Oncol Rep; 1998; 5(1):205-8. PubMed ID: 9458323
[TBL] [Abstract][Full Text] [Related]
4. Case report: development of hepatocellular carcinoma in a patient with chronic hepatitis C infection after a complete and sustained response to interferon-alpha.
Hirashima N; Mizokami M; Orito E; Koide T; Itazu I; Kumada K; Sakakibara K; Kano H; Lau JY
J Gastroenterol Hepatol; 1996 Oct; 11(10):955-8. PubMed ID: 8912134
[TBL] [Abstract][Full Text] [Related]
5. Interferon and hepatocellular carcinoma.
Andreone P; Cursaro C; Gramenzi A; Trevisani F; Gasbarrini G; Bernardi M
Lancet; 1996 Jan; 347(8995):195. PubMed ID: 8544566
[No Abstract] [Full Text] [Related]
6. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.
Mazzella G; Accogli E; Sottili S; Festi D; Orsini M; Salzetta A; Novelli V; Cipolla A; Fabbri C; Pezzoli A; Roda E
J Hepatol; 1996 Feb; 24(2):141-7. PubMed ID: 8907566
[TBL] [Abstract][Full Text] [Related]
7. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
Shindo M; Ken A; Okuno T
Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
[TBL] [Abstract][Full Text] [Related]
8. Effect of the dose and duration of interferon-alpha therapy on the incidence of hepatocellular carcinoma in noncirrhotic patients with a nonsustained response to interferon for chronic hepatitis C.
Toyoda H; Kumada T; Nakano S; Takeda I; Sugiyama K; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Hayashi K; Honda T
Oncology; 2001; 61(2):134-42. PubMed ID: 11528252
[TBL] [Abstract][Full Text] [Related]
9. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival.
Shiratori Y; Ito Y; Yokosuka O; Imazeki F; Nakata R; Tanaka N; Arakawa Y; Hashimoto E; Hirota K; Yoshida H; Ohashi Y; Omata M;
Ann Intern Med; 2005 Jan; 142(2):105-14. PubMed ID: 15657158
[TBL] [Abstract][Full Text] [Related]
10. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
[TBL] [Abstract][Full Text] [Related]
11. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis.
Hung CH; Lee CM; Lu SN; Wang JH; Hu TH; Tung HD; Chen CH; Chen WJ; Changchien CS
J Viral Hepat; 2006 Jun; 13(6):409-14. PubMed ID: 16842444
[TBL] [Abstract][Full Text] [Related]
12. [Treatment with interferon alfa-2b in patients with chronic hepatitis caused by hepatitis C virus: predictive factors for the response, relapse and early development to cirrhosis after treatment].
Pérez Roldán F; De Diego A; Casado M; Matilla A; Bañares R; García-Durán F; Salcedo M; Cos E; Clemente G
Rev Esp Enferm Dig; 1996 Sep; 88(9):609-15. PubMed ID: 8962775
[TBL] [Abstract][Full Text] [Related]
13. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment.
Valla DC; Chevallier M; Marcellin P; Payen JL; Trepo C; Fonck M; Bourliere M; Boucher E; Miguet JP; Parlier D; Lemonnier C; Opolon P
Hepatology; 1999 Jun; 29(6):1870-5. PubMed ID: 10347132
[TBL] [Abstract][Full Text] [Related]
14. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.
Yoshida H; Shiratori Y; Moriyama M; Arakawa Y; Ide T; Sata M; Inoue O; Yano M; Tanaka M; Fujiyama S; Nishiguchi S; Kuroki T; Imazeki F; Yokosuka O; Kinoyama S; Yamada G; Omata M
Ann Intern Med; 1999 Aug; 131(3):174-81. PubMed ID: 10428733
[TBL] [Abstract][Full Text] [Related]
15. A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development.
Kashiwagi K; Furusyo N; Kubo N; Nakashima H; Nomura H; Kashiwagi S; Hayashi J
J Infect Chemother; 2003 Dec; 9(4):333-40. PubMed ID: 14691655
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP).
Fattovich G; Giustina G; Degos F; Diodati G; Tremolada F; Nevens F; Almasio P; Solinas A; Brouwer JT; Thomas H; Realdi G; Corrocher R; Schalm SW
J Hepatol; 1997 Jul; 27(1):201-5. PubMed ID: 9252096
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of cryoglobulinemia in chronic hepatitis C virus infection and response to treatment with interferon-alpha.
Akriviadis EA; Xanthakis I; Navrozidou C; Papadopoulos A
J Clin Gastroenterol; 1997 Dec; 25(4):612-8. PubMed ID: 9451674
[TBL] [Abstract][Full Text] [Related]
18. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis.
Nishiguchi S; Shiomi S; Nakatani S; Takeda T; Fukuda K; Tamori A; Habu D; Tanaka T
Lancet; 2001 Jan; 357(9251):196-7. PubMed ID: 11213099
[TBL] [Abstract][Full Text] [Related]
19. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
20. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
J Med Virol; 2007 Oct; 79(10):1485-90. PubMed ID: 17705189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
